Physician

Melhem Jabbour, M.D.

According to 2025 Medicare claims, Melhem Jabbour, M.D. (NPI: 1851697536) practices hematology/oncology in the Terre Haute, IN market, with the plurality of this provider's patient population coming from Vigo, IN. This provider's primary affiliated billing organization is UNION HOSPITAL, INC. (NPI: 1013965573; TIN: 350876396) and primary practice location at 47802-3562. Jabbour is affiliated with the Ascension Care Management (ACO ID: A2600), IRCCO (ACO ID: A2619), Central Florida ACO (ACO ID: A2801), and Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Jabbour's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 751 traditional Medicare patients, billed 2,669 HCPCS/CPT codes, and received $177,506 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,124 prescription claims across 285 beneficiaries totaling $2,482,715 in drug costs, led by Lenalidomide (Lenalidomide). 2023 DME data shows 42 claims. Open Payments data shows 195 records totaling $4,383. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $221,510 to $2,482,715. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $5,549 and ending at $1,896.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	426	1,744	$130,264
2016	508	2,312	$150,668
2017	656	3,411	$237,951
2018	736	3,420	$220,763
2019	742	3,738	$215,439
2020	752	3,730	$223,406
2021	701	3,660	$214,531
2022	685	3,021	$187,118
2023	700	2,565	$162,674
2024	751	2,669	$177,506

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	91	505	$221,510
2016	118	695	$294,676
2017	151	840	$587,270
2018	182	939	$1,255,892
2019	206	1,237	$2,317,645
2020	218	1,306	$2,898,644
2021	235	1,493	$2,149,114
2022	228	1,236	$2,734,390
2023	242	1,073	$2,634,236
2024	285	1,124	$2,482,715

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	74	$5,498
2016	N/R	16	$1,253
2017	N/R	14	$57
2018	N/R	38	$850
2019	N/R	N/R	N/R
2020	N/R	34	$1,858
2021	N/R	33	$2,325
2022	N/R	40	$1,928
2023	N/R	42	$7,086
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	185	293	$91
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	273	352	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	531	1,162	$63
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	158	217	$57
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	188	489	$36

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	25	700	$417,285
Pomalyst	Pomalidomide	12	336	$273,002
Revlimid	Lenalidomide	12	336	$217,749
Jakafi	Ruxolitinib Phosphate	11	330	$152,189
Kisqali	Ribociclib Succinate	12	336	$148,264

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	195	$4,383	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Melhem Jabbour, M.D.?

Tedicare shows public-source Medicare data for Melhem Jabbour, M.D. (NPI 1851697536), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Melhem Jabbour, M.D. have ACO affiliation data?

Melhem Jabbour, M.D. is shown with ACO affiliation data for Ascension Care Management (MSSP, ACO ID A2600), IRCCO (MSSP, ACO ID A2619), Central Florida ACO (MSSP, ACO ID A2801), and Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Melhem Jabbour, M.D.?

Melhem Jabbour, M.D. is linked to UNION HOSPITAL, INC. (billing NPI 1013965573) in the available physician profile data.

Does Melhem Jabbour, M.D. have Open Payments data?

Melhem Jabbour, M.D. has 195 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.